iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla launches RT Direct multiplex real time PCR kit for Covid-19

10 May 2022 , 08:46 AM

Cipla announced the commercialisation of RT-Direct multiplex COVID-19 RT PCR test kit in India, in partnership with Genes2Me. With this Cipla is expanding its diagnostics offering to bring more advance and innovative products. This kit is validated at the Indian Council of Medical Research (ICMR) approved Centre. It is based on the gold standard RT-PCR method with coverage of three target genes specific to SARS-COV-2 along with IC, which is much advanced than others having 1 or 2 target genes. This greatly increases the sensitivity of the RTPCR test. RT-Direct test protocol does not require any RNA extraction process, making it faster and helps deliver results in just 45 minutes. It will also increase the throughput of any testing lab by threefold compared to the normal RT-PCR test protocol time of 120-150 minutes. Cipla is a global pharmaceutical company focused on India, South Africa, North America, and key regulated and emerging markets. The drug company reported a 2.6% decline in consolidated net profit to Rs 729 crore in Q3 FY22 from Rs 748 crore posted in Q3 FY21. Total revenue from operations grew by 6% year on year to Rs 5,479 crore in Q3 FY22 over Q3 FY21. Shares of Cipla rose 0.25% at Rs 937.55 on Monday. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.